Back to results
US 2019/0100530 A1Published application
Bicyclic ketone compounds and methods of use thereof
AssigneeGenentech, Inc.
InventorsSnahel PATEL, Gregory HAMILTON, Guiling ZHAO, Huifen CHEN, Blake DANIELS, Craig STIVALA
Life of this patent
Estimating the term…
Abstract
The invention provides novel compounds having the general formula I: wherein R1, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.
Claims28
A compound of formula (I):
- or pharmaceutically acceptable salts thereof, wherein
- R1 is selected from the group consisting of C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, C1-C6 alkyl-N(RN)2, phenyl, benzyl, 4 to 8 membered heterocyclyl and 5 to 6 membered heteroaryl;
- wherein R1 is bound to the adjacent carbonyl by a carbon atom, and wherein R1 is optionally substituted by one or two substituents selected from the group consisting of F, Cl, Br, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, C1-C6 alkyl-N(RN)2, hydroxyl, hydroxymethyl, cyano, cyanomethyl, cyanoethyl, C(O)C1-C6 alkyl, phenyl, benzyl, CH2—(C3-C6 cycloalkyl), 5 to 6 membered heteroaryl, and CH2-(5 to 6 membered heteroaryl);
- each RN is independently selected from the group consisting of H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, and C1-C6 haloalkyl;
- or two RN may together with the adjacent N form a 4-6 membered ring;
- the A ring is a 5 membered heteroaryl having as the only heteroatoms, either (i) two or three nitrogen atoms, (ii) one nitrogen atom and one oxygen atom, or (iii) one nitrogen atom and one sulfur atom;
- wherein the A ring is bound to the adjacent carbonyl by a carbon atom;
- and
- the B ring is a 4 to 8 membered cycloalkyl, or a 4 to 8 membered heterocyclyl having 1 to 3 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur;
- wherein the B ring is substituted according to (a), (b), or both (a) and (b):
- (a) 1 to 2 substituents selected from the group consisting of halogen, deuterium, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 thioalkyl, C1-C6 alkyl-N(RN)2, and cyano;
- wherein two C1-C6 alkyl substituents may together for a bridged or spirocyclic ring;
- and wherein if a nitrogen atom in the B ring is substituted, the substituent is not halogen, cyano, or a C1-C6 alkoxy, C1-C6 haloalkoxy or C1-C6 thioalkyl having an oxygen or sulfur atom directly bonded to the nitrogen atom;
- (b) 1 substituent selected from the group consisting of C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 thioalkyl, C1-C6 alkyl-N(RN)2, phenyl, benzyl, CH2—(C3-C6 cycloalkyl), CH2CH2—(C3-C6 cycloalkyl), CH2-(4 to 6 membered heterocyclyl), CH2CH2-(4 to 6 membered heterocyclyl), 5 to 6 membered heteroaryl, and CH2-(5 to 6 membered heteroaryl);
- wherein when a phenyl ring or 5 to 6 membered heteroaryl ring is present it may be substituted by 1 to 3 substituents selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, cyano, and cyclopropyl.
12 more elements
A pharmaceutical composition comprising a compound of 1, or a pharmaceutically acceptable salt thereof, and a therapeutically inert carrier.
Dependencies are inferred from the claim text.